After Revolution Medicines' 300% run, Morgan Stanley's Overweight is a certification, not a signal

The headline reads like a fresh flag: Morgan Stanley started covering Revolution Medicines (RVMD) with an Overweight rating and a $255 price target, anchored on its RAS-targeted oncology franchise. The quant version of the same story is less glamorous and more useful. This is a re-rating the market already executed. RVMD is up more than 300% over the trailing year and 156% so far in 2026, and the new target sits only about a quarter above the ~$204 price where the stock trades today.

What changed, and how big it was

Before the run, RVMD was a clinical-stage bet. It became a commercial-stage company on August 26, when the FDA approved Rasonque (daraxonrasib) as a first-in-class RAS-targeted therapy for previously treated metastatic pancreatic cancer, pulled in months ahead of schedule. The approval rests on data that genuinely cleared the bar: in the RASolute 302 trial, daraxonrasib nearly doubled median overall survival versus chemotherapy, to 13.2 months from 6.7, with a hazard ratio of 0.40. Progression-free survival roughly doubled as well. For a cancer as notoriously aggressive as pancreatic, that is the kind of result that forces a permanent re-pricing of the story rather than a one-week pop.

A screen that can't do its normal job

I'll be direct about what my factor grades can and cannot tell you here, because the honest answer changes how you should think about the stock. My framework scores a name on valuation, growth, profitability, momentum, and earnings revisions against a peer set. RVMD breaks three of those five.

There are no earnings to grade — trailing price-to-earnings is negative and price-to-book is above 16. There is no meaningful profitability or cash-flow valuation for a company still burning through cash at roughly $1.2 billion a year. That is not the process calling the stock wrong; it is the process telling you it cannot apply its standard tools, so the judgment has to lean on the two factors it can still measure: revisions and momentum, plus the balance sheet that keeps the engine funded.

On those, the report card is genuinely strong. This is not a case where a low absolute multiple looks cheap. RVMD carries a market cap near $44 billion — roughly eight times the size of Erasca, the next-largest pure-play trading on the same RAS story — so the "cheap versus peers" frame never applies. The supporting case is everything else. Sell-side targets have been climbing as one — UBS pegged the drug's probability of success at 100%, and several firms now sit between $260 and $280 — placing Morgan Stanley's $255 toward the conservative end even of a bullish group. The stock holds well above both its 50- and 200-day moving averages. In the language of the framework, the momentum and revisions factors confirm the growth story rather than contradict it.

The safety input is also real. Revolution ended the second quarter with $3.9 billion in cash and investments, against full-year 2026 operating-expense guidance of $2.1–2.2 billion, plus a committed Royalty Pharma funding backstop and, now, commercial revenue. That is roughly two years of runway against a rising burn — not a company running on fumes.

What the $44 billion is actually paying for

Here is the number that does the real work, and it is not the first approval. Second-line pancreatic cancer is a small market, and at a wholesale cost of about $39,800 for a 30-day supply, Rasonque alone does not justify a $44 billion valuation. The market is paying for the franchise beyond it: zoldonrasib, the company's G12D-selective compound, which has already shown a 52% confirmed response rate and an 11.1-month median progression-free survival in KRAS G12D non-small cell lung cancer — a far larger patient pool — plus combos pairing the two agents and earlier programs across the RAS landscape.

That is where the growth argument earns its keep, and exactly where the risk lives. A little more than a year ago this was a single-asset, pre-revenue story at $42. Today the market is capitalizing drugs that are still in trials on the strength of an approval that, though real, opens a limited commercial window. The launch's task — converting expanded-access demand into paid prescriptions — and the next Phase 3 readouts are the variables that will decide whether the re-rating holds.

The portfolio conclusion follows from the factor stack rather than from conviction about the science. This is a high-beta, high-conviction catalyst position, not a core sleeve: it carries no value, income, or safety anchor to stand on, so it should be sized to tolerate clinical drawdowns and paired against the dividend and cash-flow side of a barbell, not loaded up on because the chart worked. The trigger that would change the call is not the $255 target — with sentiment this uniformly bullish, a price target is the least informative number in the story. It is whether zoldonrasib and the combos keep raising the ceiling in bigger populations, and whether Rasonque's launch converts into real prescription growth.